🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Bio-Techne, Regulus report progress in ADPKD study

Published 05/23/2024, 12:54 AM

MINNEAPOLIS - Bio-Techne (NASDAQ:TECH) Corporation (NASDAQ: TECH) and Regulus (NASDAQ:RGLS) Therapeutics Inc. have announced the continuation of their technical and clinical collaboration, following the release of positive topline results from a Phase 1b study of a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The collaboration, which began in 2020, supports the development of therapies targeting microRNAs, specifically anti-miR-17, for ADPKD treatment.

The topline clinical data for Regulus' investigational drug RGLS8429 was generated using Bio-Techne's Simple WesternTM platforms and ExosomeDx CLIA laboratory services. These technologies automate western blotting processes and provide liquid biopsy-based diagnostics, respectively, facilitating the analysis of protein expression and the identification of therapeutic proteins.

In the study, Regulus developed assays to measure levels of polycystin 1 (PC1) and polycystin 2 (PC2) in urine samples. These biomarkers are significant for ADPKD as affected patients typically have low levels of these proteins. The assays provide sensitive and quantitative readouts, which are crucial for understanding the drug's mechanism and pharmacodynamics.

Will Geist, President of Bio-Techne's Protein Sciences Segment, commended the Regulus team for the milestone and expressed enthusiasm for the continued partnership. Bio-Techne, with a portfolio of thousands of products and over $1.1 billion in net sales for fiscal 2023, aims to support the development of advanced therapeutics and improve global healthcare.

Regulus Therapeutics, headquartered in San Diego, CA, is dedicated to discovering and developing medicines that target microRNAs. The company's pipeline is complemented by a robust intellectual property estate in the microRNA field.

This announcement is based on a press release statement.

InvestingPro Insights

As Bio-Techne Corporation (NASDAQ: TECH) continues to strengthen its collaboration with Regulus Therapeutics, it's noteworthy to consider the financial metrics and market performance of the company. Bio-Techne, known for its innovative platforms in protein sciences, has a market capitalization of 13.03 billion USD, reflecting its significant presence in the biotechnology market. The company's P/E ratio stands at a high 64.35, indicating investors' willingness to pay a premium for its earnings, perhaps due to the growth prospects and innovative edge it maintains in the industry.

InvestingPro data indicates that Bio-Techne's revenue for the last twelve months as of Q3 2024 is 1.154 billion USD, with a revenue growth of 2.73%. This growth is modest but stable, which may reassure investors looking for steady progress in the biotech sector. Additionally, the company's gross profit margin is a robust 67.01%, showcasing its ability to maintain profitability despite the costs associated with research and development.

From an investment standpoint, Bio-Techne has been trading at a high Price / Book multiple of 6.47, suggesting that the market values it above its book value, possibly due to the potential of its technologies and collaborations like the one with Regulus Therapeutics. An InvestingPro Tip to consider is that Bio-Techne's cash flows can sufficiently cover its interest payments, which is a positive sign of financial health, especially for a company in a capital-intensive industry. Furthermore, the company has upheld its dividend payments for 17 consecutive years, which could be attractive for income-seeking investors.

For investors looking for in-depth analysis and additional insights, there are more InvestingPro Tips available for Bio-Techne. These tips can provide further guidance on investment decisions, especially in the dynamic biotech sector. Interested readers can explore these tips by visiting https://www.investing.com/pro/TECH and can take advantage of an additional 10% off a yearly or biyearly Pro and Pro+ subscription using the coupon code PRONEWS24. With this offer, investors can access a wealth of information, including the numerous additional tips listed on InvestingPro, to better understand the investment landscape surrounding companies like Bio-Techne.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.